Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 22 May 2025
An analysis of several datasets cataloguing the switch revealed that dosing can be extended up to 2 weeks for patients with nAMD who received prior anti-VEGF therapy.
Read Full NewsThe recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.
The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.
1.
Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth
2.
Detecting pancreatic cancer through changes in body composition and metabolism
3.
In heavily pretreated DLBCL, Triplet Scores a Survival Victory.
4.
The pandemic had little impact on mental health symptoms.
5.
Men over 75 years old may be significantly more likely to commit suicide if they have cancer.
1.
From Muscle Soreness to Improved Endurance: The Benefits of Monitoring Lactic Acid Levels
2.
Unlocking the Mystery of Basilar Artery Stroke: A New Approach to Treatment
3.
Intrapancreatic Fat, Pancreatitis, and Cancer: Role of Cancer-Associated Fibroblasts
4.
Understanding Acute Intermittent Porphyria: Symptoms, Diagnosis and Treatment
5.
Exploring the Unknown: Unveiling the Mysteries of GIST Tumors
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
3.
Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.
4.
From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge